Linker Information
General Information of This Linker
| Linker ID |
LIN00004
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
Glycylglycylglycine
|
|||||
| Structure |
|
|||||
| Formula |
C6H11N3O4
|
|||||
| #Ro5 Violations (Lipinski): 1 | Molecular Weight (mw) | 189.17 | ||||
| Lipid-water partition coefficient (xlogp) | -3.6 | |||||
| Hydrogen Bond Donor Count (hbonddonor) | 4 | |||||
| Hydrogen Bond Acceptor Count (hbondacc) | 5 | |||||
| Rotatable Bond Count (rotbonds) | 5 | |||||
| PubChem CID | ||||||
| Canonical smiles |
C(C(=O)NCC(=O)NCC(=O)O)N
|
|||||
| InChI |
InChI=1S/C6H11N3O4/c7-1-4(10)8-2-5(11)9-3-6(12)13/h1-3,7H2,(H,8,10)(H,9,11)(H,12,13)
|
|||||
| InChIKey |
XKUKSGPZAADMRA-UHFFFAOYSA-N
|
|||||
| IUPAC Name |
2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetic acid
|
|||||
Each Peptide-drug Conjugate Related to This Linker
Full Information of The Activity Data of The PDC(s) Related to This Linker
HCPTMDP26-PEG [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Breast cancer | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
1.27 µM
|
|||
| Description |
Peptides and drug-peptide conjugates were incubated with HepG2 cells for 48 hours followed by a CCK8 cytotoxicity assay. Despite the large population of the positive charges, supramolecular peptides alone demonstrated negligible cytotoxicity (Fig. S8, ESI). The drug conjugate, HCPT-MDP26-PEG showed a dose-dependent cytotoxicity with an IC50of 1.27 uM, comparable to the IC50of free HCPT at ˜1.3 uM (Fig. 3a). At a high drug dosage, the drug conjugate is much more potent than free HCPT.
Click to Show/Hide
|
||||
| In Vitro Model | Hepatoblastoma | L-O2 cell line | CVCL_0027 | ||
References